facebook button Second Line Sitravatinib Plus Nivolumab
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Second Line Sitravatinib Plus Nivolumab

Sponsor: Mirati Therapeutics, Inc.

Protocol 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy

For more information contact the research department at 631-675-5075